In English | En español
Questions About Cancer? 1-800-4-CANCER

Clinical Trials Search Results

View Content for:
Display:
  •          
Help with display options.
Results 1-25 of 101 for your search:
Drug:  dasatinib
Find trials that include:  Any drugs shown
Trial Status:  Closed
Start Over
        Show
1.

Phase: Phase III
Type: Treatment
Status: Closed
Age: 18 to 90
Sponsor: Pharmaceutical / Industry
Protocol IDs: CA180-034, NCT00123474

2.

Phase: Phase III
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: CA180-056, 2006-005712-27, NCT00481247

3.

Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Status: Closed
Age: 1 to 30
Sponsor: NCI
Protocol IDs: NCI-2009-00312, CDR0000600217, COG-AALL0622, AALL0622, U10CA098543, NCT00720109

4.

Phase: Phase III
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: CA180-227, 2008-000701-11, NCT00744497

5.

Phase: Phase II, Phase I
Type: Treatment
Status: Completed
Age: 20 to 75
Sponsor: Pharmaceutical / Industry
Protocol IDs: CA180-031, NCT00337454

6.

Phase: Phase II, Phase I
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: CA180-086, NCT00439270

7.

Phase: Phase II, Phase I
Type: Treatment
Status: Completed
Age: 20 to 75
Sponsor: Pharmaceutical / Industry
Protocol IDs: CA180-138, NCT00482703

8.

Phase: Phase II, Phase I
Type: Treatment
Status: Closed
Age: 19 and over
Sponsor: Other
Protocol IDs: 244-07-FB, BMS Protocol 180129, NCT00550615

9.

Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Closed
Age: 18 and over
Sponsor: Other
Protocol IDs: 2006-0900, NCT00566618

10.

Phase: Phase II, Phase I
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Other
Protocol IDs: MCC-15256, 106128, CA180-092, NCT00597038

11.

Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Closed
Age: 1 to 25
Sponsor: NCI, Other
Protocol IDs: 07053, P30CA033572, CHNMC-07053, CA180 121, CDR0000617760, NCT00788125

12.

Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Closed
Age: 16 and over
Sponsor: Other
Protocol IDs: 2008-0353, NCT00826449

13.

Phase: Phase II, Phase I
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: Other
Protocol IDs: AMLSG 11-08, NCT00850382

14.

Phase: Phase II, Phase I
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Other
Protocol IDs: ALSSMBC0804, NCT00924352

15.

Phase: Phase II, Phase I
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: Other
Protocol IDs: UCSD 110054 - Prev 080422, NCT00949988

16.

Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: CA180-323, 2010-019480-11, NCT01218477

17.

Phase: Phase II, Phase I
Type: Treatment
Status: Closed
Age: 16 and over
Sponsor: Other
Protocol IDs: 2011-0254, NCI-2011-03531, NCT01460498

18.

Phase: Phase II
Type: Treatment
Status: Closed
Age: 70 and under
Sponsor: NCI, Other
Protocol IDs: 1581.00, NCI-2010-00131, P01CA018029, P30CA015704, FHCRC-1581.00, 5235, NCI-H02-0087, NCT00036738

19.

Phase: Phase II
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: NCI
Protocol IDs: NCI-2009-00764, S0325, U10CA032102, SWOG-S0325, ECOG-S0325, NCT00070499

20.

Phase: Phase II
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: CA180-015, NCT00101595

21.

Phase: Phase II
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: CA180-005, NCT00101647

22.

Phase: Phase II
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: CA180-013, NCT00101660

23.

Phase: Phase II
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: CA180-006, NCT00101816

24.

Phase: Phase II
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: CA180-017, NCT00103844

25.

Phase: Phase II
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: NCI, Pharmaceutical / Industry
Protocol IDs: UCLA-0501047-01, BMS-CA180017, EUDRACT-2004-004450-96, NCT00112775
1     
New Search